Portella, MJ, Arteaga-Henríquez, G, de Diego-Adeliño, J, Trujols, J, Puigdemont, D, Pérez, J, Alemany, C, Carrasco-Hernández, J, Udina, M, Cardoner, N, Vicent-Gil, M. Linking cognitive function and biological markers in depression: Can IL-6 plasma levels and attention domain be used as an ensemble classification system?. GENERAL HOSPITAL PSYCHIATRY. 2025; 92DOI:10.1016/j.genhosppsych.2024.10.003. PMID:39395857. IF:3.700(Q1/3D).

Seppälä, J, Grasa, E, Alonso-Solis, A, Roldan-Bejarano, A, Haapea, M, Isohanni, M, Miettunen, J, Mendivelso, JC, Almazán, C, Rubinstein, K, Caspi, A, Unoka, Z, Farkas, K, Reixach, E, Berdun, J, Usall, J, Ochoa, S, Corripio, I, Jääskeläinen, E. Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy Study. Jmir Human Factors. 2025; 12DOI:10.2196/67659. PMID:40372941. IF:(Q/D).

Casanovas, F, Dinamarca, F, Posso, M, Mané, A, Oller, S, Córcoles, D, Macià, F, Sala, M, Pérez-Sola, V, Ruiz, AI. Cancer characteristics in patients with schizophrenia: a 25-year retrospective analysis. PSYCHIATRY RESEARCH. 2024; 342DOI:10.1016/j.psychres.2024.116206. PMID:39321636. IF:3.900(Q1/2D).

Núñez, C, Stephan-Otto, C, Roldán, A, Grasa, EM, Escartí, MJ, García-Iturrospe, EJA, García-Martí, G, de la Iglesia-vaya, M, Nacher, J, Portella, MJ, Corripio, I. Orbitofrontal cortex hypergyrification in hallucinating schizophrenia patients: Surface ratio as a promising brain biomarker. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024; 89DOI:10.1016/j.euroneuro.2024.09.006. PMID:39341083. IF:6.700(Q1/1D).